<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838743</url>
  </required_header>
  <id_info>
    <org_study_id>NN9068-4743</org_study_id>
    <secondary_id>U1111-1253-2025</secondary_id>
    <secondary_id>jRCT1051210008</secondary_id>
    <nct_id>NCT04838743</nct_id>
  </id_info>
  <brief_title>GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan.</brief_title>
  <acronym>GOAL</acronym>
  <official_title>A Non-interventional, Single-arm, Multicentre, Prospective Study Investigating the Glycaemic Control and Treatment Pattern Associated With the Use of Xultophy® (IDegLira) in a Real-world Adult Population With Type 2 Diabetes Mellitus in Japan. GOAL (Glycaemic Outcome Assessment IDegLira) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect information on how Xultophy® works with other oral&#xD;
      anti diabetic medication in patients with type 2 diabetes.&#xD;
&#xD;
      Participants will get Xultophy® as prescribed by the study doctor. The study will last for&#xD;
      about 26 weeks. Participants will be asked questions about health and diabetes treatment and&#xD;
      lab tests as part of normal doctor's appointment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">August 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 22, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in local laboratory measured HbA1c (Glycated haemoglobin )</measure>
    <time_frame>From baseline (Visit 1) to 26 weeks (Visit 3)</time_frame>
    <description>% point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in local laboratory measured FPG (Fasting plasma glucose )</measure>
    <time_frame>From baseline (Visit 1) to 26 weeks (Visit 3)</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient-reported non-severe hypoglycaemic after initiation of treatment with Xultophy®</measure>
    <time_frame>From baseline (Visit 1) to 26 weeks (Visit 3)</time_frame>
    <description>Count of episodes&#xD;
Non-severe hypoglycaemia: Defined as an episode with patient reported symptoms and/or self-measured plasma glucose value below 3.9 mmol/L (70 mg/dL). episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient-reported severe hypoglycaemic after initiation of treatment with Xultophy®</measure>
    <time_frame>From baseline (Visit 1) to 26 weeks (Visit 3)</time_frame>
    <description>Count of episodes&#xD;
Severe hypoglycaemia: Defined as an episode of hypoglycaemia requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective action episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concomitant OAD(s) (Oral antidiabetic drugs ) including change in number, class, and frequency of concomitant OAD(s), after initiation of treatment of Xultophy® (Yes/No)</measure>
    <time_frame>From baseline (Visit 1) to 26 weeks (Visit 3)</time_frame>
    <description>Count of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in daily dose of Xultophy®</measure>
    <time_frame>From baseline (Visit 1) to 26 weeks (Visit 3)</time_frame>
    <description>Dose</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">244</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>IDegLira</arm_group_label>
    <description>Real-world adult population with type 2 diabetes mellitus in Japan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDegLira</intervention_name>
    <description>Patients will be treated with commercially available Xultophy® (IDegLira) in a pre-filled pen injector (FlexTouch®) at the discretion of the treating physician in accordance with the Xultophy® label in Japan.&#xD;
The decision to initiate treatment with Xultophy® is at the treating physician's discretion according to the approved Xultophy® label in Japan and independent from the decision to include the patient in the study.</description>
    <arm_group_label>IDegLira</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Real-world adult population with type 2 diabetes mellitus in Japan&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed consent obtained before any study-related activities (study-related activities&#xD;
             are any procedure related to recording of data according to the protocol).&#xD;
&#xD;
          -  The decision to initiate treatment with commercially available Xultophy® has been made&#xD;
             by the patient/Legally Acceptable Representative (LAR) and the treating physician&#xD;
             before and independently from the decision to include the patient in this study.&#xD;
&#xD;
          -  Male or female, age above or equal to 20 years at the time of signing informed consent&#xD;
&#xD;
          -  Diagnosed with T2DM (Type 2 diabetes mellitus ) above or equal to 180 days prior to&#xD;
             initiation of Xultophy® treatment.&#xD;
&#xD;
          -  Treated with any oral anti-hyperglycaemic medication(s), except for oral GLP-1 RAs,&#xD;
             for at least 60 days prior to initiation of Xultophy® treatment.&#xD;
&#xD;
          -  Available and documented HbA1c value less or equal to 12 weeks prior to initiation of&#xD;
             Xultophy® treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous participation in this study. Participation is defined as having given&#xD;
             informed consent in this study.&#xD;
&#xD;
          -  Participation in any clinical trial of an approved or non-approved investigational&#xD;
             medicinal product within 30 days before prior to initiation of Xultophy® (Simultaneous&#xD;
             participation in a trial with the primary objective of evaluating an approved or&#xD;
             non-approved investigational medicinal product for prevention or treatment of COVID-19&#xD;
             disease or postinfectious conditions is allowed if the last dose of the&#xD;
             investigational medicinal product has been received more than 30 days before&#xD;
             screening.).&#xD;
&#xD;
          -  Treatment with any medication for the indication of diabetes or obesity other than&#xD;
             stated in the inclusion criteria within the past 60 days prior to initiation of&#xD;
             Xultophy® treatment. However, short term insulin treatment for a maximum of 14 days&#xD;
             prior to initiation of Xultophy® treatment is allowed, as is prior insulin treatment&#xD;
             for gestational diabetes.&#xD;
&#xD;
          -  Previous treatment with Xultophy®.&#xD;
&#xD;
          -  Female who is known pregnant, breast-feeding or intends to become pregnant.&#xD;
&#xD;
          -  Mental incapacity, unwillingness or language barriers precluding adequate&#xD;
             understanding or cooperation.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to the active substance or to any of the&#xD;
             excipients as specified in the approved Xultophy® label in Japan.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>468-0009</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Arakawa-ku, Tokyo</city>
        <zip>116-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Asahikawa-shi, Hokkaido</city>
        <zip>070-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bunkyo-ku, Tokyo</city>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>299-1144</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <zip>103-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ehime</city>
        <zip>790-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fukuoka-shi, Fukuoka</city>
        <zip>819-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gunma</city>
        <zip>373-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>235-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>253-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kitakyusyu-shi, Fukuoka</city>
        <zip>802-0974</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kochi-shi, Kochi</city>
        <zip>780-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kumamoto</city>
        <zip>862-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kurashiki-shi, Okayama</city>
        <zip>701-0192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Minato-ku</city>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Naka-shi</city>
        <zip>311 0113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oita-shi, Oita</city>
        <zip>870-0955</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oita-shi, Oita</city>
        <zip>8700831</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oita-shi</city>
        <zip>870 0039</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oita</city>
        <zip>879-7301</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Okawa-shi, Fukuoka</city>
        <zip>831-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Osaka-shi</city>
        <zip>553-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>553-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>591-8006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saga-shi, Saga</city>
        <zip>8400054</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shizuoka-shi, Shizuoka</city>
        <zip>424-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tamana-shi, Kumamoto</city>
        <zip>865 0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tochigi</city>
        <zip>323-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>190-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>206-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Yamato-shi, Kanagawa</city>
        <zip>242-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Xultophy</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

